|
[1]
|
Villanueva, A. (2019) Hepatocellular Carcinoma. New England Journal of Medicine, 380, 1450-1462. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Llovet, J.M., Kelley, R.K., Villanueva, A., Singal, A.G., Pikarsky, E., Roayaie, S., et al. (2021) Hepatocellular Carcinoma. Nature Reviews Disease Primers, 7, Article No. 6. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Harsha, C., Banik, K., Ang, H.L., Girisa, S., Vikkurthi, R., Parama, D., et al. (2020) Targeting AKT/mTOR in Oral Cancer: Mechanisms and Advances in Clinical Trials. International Journal of Molecular Sciences, 21, Article No. 3285. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Pan, Z., Tian, Y., Cao, C. and Niu, G. (2019) The Emerging Role of YAP/TAZ in Tumor Immunity. Molecular Cancer Research, 17, 1777-1786. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
王鹏, 等. 抑制JAK/STAT信号通路对肝癌细胞生物学行为的调控及机制[J]. 中国普通外科杂志, 2025, 34(8): 1709-1717.
|
|
[6]
|
杜恒, 等. HBX蛋白与M2巨噬细胞介导肝癌细胞上皮间质转化的实验研究[J]. 中华普通外科杂志, 2016, 31(6): 497-500.
|
|
[7]
|
Koundouros, N. and Poulogiannis, G. (2019) Reprogramming of Fatty Acid Metabolism in Cancer. British Journal of Cancer, 122, 4-22. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Zou, Z., Tao, T., Li, H. and Zhu, X. (2020) mTOR Signaling Pathway and mTOR Inhibitors in Cancer: Progress and Challenges. Cell & Bioscience, 10, Article No. 31. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Rahmani, F., Ziaeemehr, A., Shahidsales, S., Gharib, M., Khazaei, M., Ferns, G.A., et al. (2019) Role of Regulatory miRNAs of the PI3K/AKT/mTOR Signaling in the Pathogenesis of Hepatocellular Carcinoma. Journal of Cellular Physiology, 235, 4146-4152. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
王守峰, 等. 不同Child分级的高HBVDNA滴度原发性肝癌介入治疗后肝功能损害的对比研究[J]. 中国肿瘤外科杂志, 2013, 5(3): 160-162.
|
|
[11]
|
茆丽娜, 等. 急诊可切除破裂出血肝癌患者治疗策略的选择及预后因素分析[J]. 介入放射学杂志, 2022, 31(6): 572-576.
|
|
[12]
|
闫晓彤, 等. 抗病毒治疗对血清AFP在HBV感染相关肝癌诊断应用中的影响[J]. 郑州大学学报(医学版), 2018, 53(5): 557-560.
|